CompletedNCT01914393
Long-Term Lurasidone Safety in Young People With Schizophrenia or Bipolarity-Related Depression
About this title
Read the official source — NCT01914393Medication studyAges 6–17Multiple countries
Understand this study
Who was this study for?
Listed age limits: 6 years to 17 years.
- Listed locations
- Dothan and 87 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: September 30, 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 702
- Sponsor
- Sumitomo Pharma America, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Bulgaria, ...
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT01914393
- Official title
Show the full official title
A 104-Week, Flexible-Dose, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of Lurasidone in Pediatric Subjects
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Dothan, United States · Downey, United States · San Francisco, United States
79 more locations
- Santa Ana, United States
- Gainesville, United States
- Orlando, United States
- Sanford, United States
- St. Petersburg, United States
- Tampa, United States
- Atlanta, United States
- Smyrna, United States
- Overland Park, United States
- Lexington, United States
- Lake Charles, United States
- Baltimore, United States
- Bloomfield Hills, United States
- Saint Charles, United States
- Neptune City, United States
- Glen Oaks, United States
- Mount Kisco, United States
- New York, United States
- Rochester, United States
- Staten Island, United States
- Cincinnati, United States
- Cleveland, United States
- Columbus, United States
- Oklahoma City, United States
- Dallas, United States
- The Woodlands, United States
- Clinton, United States
- Charlottesville, United States
- Herndon, United States
- Petersburg, United States
- Roanoke, United States
- Rousse, Bulgaria
- Sofia, Bulgaria
- Targovishte, Bulgaria
- Varna, Bulgaria
- Barranquilla, Colombia
- Bello, Colombia
- Bogotá, Colombia
- Nantes, France
- Budapest, Hungary
- Gyula, Hungary
- Kuala Lumpur, Malaysia
- Culiacán, Mexico
- Durango, Mexico
- Monterrey, Mexico
- Nuevo León, Mexico
- Davao City, Philippines
- Iloilo City, Philippines
- Mandaluyong, Philippines
- Quezon City, Philippines
- Kobierzyce, Poland
- Torun, Poland
- Caguas, Puerto Rico
- Bucharest, Romania
- Iași, Romania
- Timișoara, Romania
- Lipetsk, Russia
- Moscow, Russia
- Nizhny Novgorod, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Tomsk, Russia
- Yaroslavl, Russia
- Yekaterinburg, Russia
- Seoul, South Korea
- Gwangju, South Korea
- Incheon, South Korea
- Jeonju, South Korea
- Torremolinos, Spain
- Ivano-Frankivsk, Ukraine
- Kharkiv, Ukraine
- Kyiv, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- Stepanovka, Ukraine
- Ternopil, Ukraine
- Vinnitsia, Ukraine
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Sumitomo Pharma America, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Lurasidone 20, 40, 60, 80 mg, flexibly dosed.
Who was this study for?
Listed age limits: 6 years to 17 years.
Want to explore more studies?
Explore studiesRelated studies
A randomized controlled clinical trial for assessing the effectiveness of pharmacogenetic information obtained with NEUROFARMAGEN in the treatment of patients with mental disorders
A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode